UCB’s Post

What does it mean to go beyond traditional CDMO services? NorthX Biologics CEO, Janet Hoogstraate shares her thoughts. ➡️ Are you ready to bring your next biologics project to life? Let's journey together to turn visionary science into life-changing treatments for patients. https://lnkd.in/d5DS-zRu #BeyondCDMO

A European team, led by London partners Tom Brassington and Penny Powell, has advised Novartis on its sale of Advanced Accelerator Applications Molecular Imaging to Siemens Healthineers. Advanced Accelerator Applications Molecular Imaging is a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. Find out more about the transaction here: https://lnkd.in/ei5HAsXD #MergersAndAcquisitions #LifeSciences #HealthCare #Pharmaceuticals #Manufacturing #Technology

Increíble !!! With around 70% of immune and central nervous system diseases still classified as having unmet medical needs, accelerating the discovery of effective therapies is critical. XtalFold will allow us to leverage structural insights into the entire antibody discovery and optimisation workflow; allowing us to be more efficient in how we select and engineer antibodies with suitable drug-like properties.

A European team, led by London partners Tom Brassington and Penny Powell, has advised Novartis on its sale of Advanced Accelerator Applications Molecular Imaging to Siemens Healthineers. Advanced Accelerator Applications Molecular Imaging is a European manufacturing and distribution network of diagnostic radiopharmaceuticals for positron emission tomography (PET) scans. Find out more about the transaction here: https://lnkd.in/eSWgRrjh #MergersAndAcquisitions #LifeSciences #HealthCare #Pharmaceuticals #Manufacturing #Technology

Check out the latest roundtable with Pharma's Almanac and hear from Lexitas CEO Jeanne Hecht and other industry leaders as they discuss how advancements in technology are reshaping the roles and capabilities of CDMOs and CROs. https://lnkd.in/gVyTWxE3 #clinicalresearch #CRO #ophthalmology #innovation #technology #Lexitas

A partnership with an eye on the future! UCB and Ailux Biologics are uniting vision and technology to explore the full potential of biologics research. Beyond immediate breakthroughs, this collaboration fosters a forward-thinking approach designed to redefine therapeutic possibilities. Discover how this dual commitment to innovation and patient care aims to create new opportunities in healthcare. Read more https://lnkd.in/e8FEsSGW

A new review highlights the complexities of comparing #psoriasis treatments due to various clinical trial designs and methods. With a focus on biologics and oral therapies, this research emphasizes the need for careful evaluation of variations in study design and analytical methodologies that affect patient efficacy outcomes. Dive into the full article to learn more. #ClinicalTrials https://ow.ly/VqEN50ST4ZM @Douglas DiRuggiero @Cynthia Trickett @Lauren Hippeli

Regeneron, Illumina invest in Truveta; Inhibrx Bio’s $150M loan https://lnkd.in/g_qfqZaf Plus, news about Bioptimus, RhyGaze, Grifols, subcutaneous Leqembi and Sling Therapeutics: Regeneron pours $119.5M into Truveta Series C: Regeneron will also work with the medical data research company to launch a … Click here to [...]

See how Genedata are supporting companies with digitalising their ADC workflows 👇

A new review highlights the complexities of comparing #psoriasis treatments due to various clinical trial designs and methods. With a focus on biologics and oral therapies, this research emphasizes the need for careful evaluation of variations in study design and analytical methodologies that affect patient efficacy outcomes. Dive into the full article to learn more. #ClinicalTrials https://ow.ly/VqEN50ST4ZM @Douglas DiRuggiero @Cynthia Trickett @Lauren Hippeli